Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX)

Historical Holders from Q2 2019 to Q3 2025

Symbol: QNCX on Nasdaq
Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 56,260,480
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 11,792,663
Holdings value: $19,221,893
% of all portfolios: 0%
Number of holders: 45
Number of buys: 22
Number of sells: -12
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
Nantahala Capital Management, LLC	10%	0%	$9,156,792	+$1,392,249	5,620,422	+18%	Nantahala Capital Management, LLC	30 Sep 2025
Sofinnova Partners SAS	2.7%	-54%	$1,185,734	-$1,188,000	1,197,711	-50%	Sofinnova Capital VIII	31 Mar 2025

Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	11,792,663	$19,221,893	+$6,863,060		$22,983	$1.63	45
2025 Q2	7,578,787	$12,505,248	+$3,952,656	$0	$19,840	$1.65	40
2025 Q1	5,230,260	$6,956,589	+$1,241,119	$4,123	$11,172	$1.33	35
2024 Q4	5,108,991	$9,553,550	+$495,078	$7,480	$1,593,934	$1.87	34
2024 Q3	5,193,769	$4,039,786	-$775,970	$0	$5,123	$0.7762	32
2024 Q2	6,247,425	$4,679,876	-$811,761	$300	$12,450	$0.7500	41
2024 Q1	7,272,011	$7,707,118	-$189,424		$20,352	$1.06	44
2023 Q4	7,451,323	$7,825,763	-$54,129		$0	$1.05	41
2023 Q3	7,501,451	$8,401,710	-$2,281,471	$0	$13,440	$1.12	40
2023 Q2	8,974,632	$13,507,225	+$1,945,492	$1,505	$63,662	$1.50	38
2023 Q1	7,677,996	$11,976,762	+$3,808,602	$6,240	$236,256	$1.56	41
2022 Q4	5,400,142	$3,438,849	-$3,310,463	$15,871	$196,415	$0.6374	46
2022 Q3	9,314,202	$12,384,077	-$3,927,969	$163,000	$299,000	$1.33	51
2022 Q2	11,700,511	$25,971,549	-$20,267,021	$257,000	$550,000	$2.22	60
2022 Q1	14,236,792	$88,111,251	-$45,899,789	$3,864,000	$2,398,000	$6.19	83
2021 Q4	19,237,596	$242,781,654	-$219,571,461	$14,288,570	$11,372,900	$12.62	95
2021 Q3	19,191,414	$1,759,087,977	+$80,924,604	$100,057,540	$94,710,106	$91.66	130
2021 Q2	18,545,330	$982,908,976	-$6,104,699	$21,989,700	$30,478,400	$53.00	104
2021 Q1	18,693,040	$673,491,454	+$37,011,077	$17,345,000	$13,505,000	$36.03	90
2020 Q4	17,656,872	$490,520,403	+$26,833,435	$17,179,000	$3,895,000	$27.78	84
2020 Q3	16,543,535	$826,995,550	+$55,308,755	$445,000	$375,000	$50.00	85
2020 Q2	15,442,796	$714,739,484	+$184,954,170			$46.30	82
2020 Q1	11,450,501	$522,757,976	+$39,593,805			$45.61	65
2019 Q4	10,588,023	$594,414,680	+$91,850,250			$56.14	51
2019 Q3	5,847,617	$144,973,494	+$81,320,822			$24.93	41
2019 Q2	2,421,805	$102,945,360	+$102,944,765			$42.51	37